Personalized vaccine plus immunotherapy shows promise in early melanoma trial
NCT ID NCT04930783
First seen Mar 28, 2026 · Last updated Apr 24, 2026 · Updated 4 times
Summary
This early-phase study tests a personalized vaccine (NeoVax) made from a patient's own tumor mutations, given alongside a drug that boosts immune cells (CDX-301) and either nivolumab or pembrolizumab (immunotherapies). The goal is to find the safest dose and see if the combination helps control melanoma that has spread or is at high risk of returning. The study involves 10 adults with stage III or IV melanoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.